高级检索
中华实验眼科杂志
期刊首页
过刊列表
高级检索
稿件发表
• 临床研究 •
ENGLISH ABSTRACT
60%剂量维替泊芬光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变的远期效果及安全性
董道权
董应丽
王志立
李舒茵
崔龙江
牛超
陈晓
作者及单位信息
·
DOI： 10.3760/cma.j.issn.2095-0160.2015.10.017
Clinical efficacy and safety of 60%-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy
Dong Daoquan
Dong Yingli
Wang Zhili
Li Shuyin
Cui Longjiang
Niu Chao
Chen Xiao
Authors Info & Affiliations
Dong Daoquan
Henan Eye Institute, Henan Eye Hospital, Zhengzhou 450003, China
Dong Yingli
Wang Zhili
Li Shuyin
Cui Longjiang
Niu Chao
Chen Xiao
·
DOI： 10.3760/cma.j.issn.2095-0160.2015.10.017
524
15
0
0
0
0
PDF下载
APP内阅读
摘要

背景近年来慢性中心性浆液性脉络膜视网膜病变(CSC)的光动力疗法(PDT)被认为是最有前景的治疗方法之一，但有关其治疗的用药剂量、远期效果及安全性的研究少见报道。

目的观察60%剂量维替泊芬PDT对慢性CSC治疗作用的远期效果及安全性。

方法采用回顾性病例分析和系列病例治疗前后自身对照研究设计。纳入2009年1月至2010年5月在河南省眼科研究所经荧光素眼底血管造影(FFA)、OCT和吲哚青绿血管造影(ICGA)检查确诊的慢性CSC患者21例25眼，其中男18例，占85.71%，女3例，占14.29%；单眼患者17例，双眼患者4例；年龄34～56岁，平均(43±5)岁。所有患者均行60%剂量维替泊芬(3.6 mg/m 2)PDT治疗，于治疗后2周、1个月和3个月进行复查，观察指标包括治疗前与治疗后3个月最佳矫正视力(BCVA)、OCT、FFA及ICGA表现的比较。所有患者均随访5年以上。

结果治疗后3个月患眼BCVA为0.9±0.2，明显优于治疗前的0.5±0.1，差异有统计学意义( t＝19.17， P＝0.00)。治疗后3个月患眼黄斑区中心凹下脉络膜厚度值为(326.56±39.47) μm，明显低于治疗前的(486.24±47.53) μm，差异有统计学意义( t ＝25.17， P＝0.00)。治疗后患眼荧光素渗漏均消失。随访5年以上，均无复发，未见全身或局部不良反应。

结论60%剂量维替泊芬PDT治疗慢性CSC的远期效果和安全性好于全剂量维替泊芬。

中心性浆液性脉络膜视网膜病变/治疗;光动力疗法;维替泊芬/剂量;荧光素眼底血管造影;吲哚青绿;体层摄影术，光学相干;视力
ABSTRACT

BackgroundIt is thought in recently that photodynamic therapy (PDT) is an effective treatment method for chronic central serous chorioretinopathy (CSC), but the dosage of verteporfin and its long-term efficacy and complications is rarely elucidated ever before.

ObjectiveThis study was to observe the long-term efficacy and safety of 60% dose verteporfin PDT for chronic CSC.

MethodsThis is a retrospective study and a self-controlled design was used.The clinical data of 25 eyes of 21 chronic CSC patients who received 60%-dose verteporfin PDT in Henan Eye Institute from January 2009 to May 2010 were reviewed, with the male 18 (85.71%) and female 3 (14.29%) as well as monocular CSC 17 patients and binocular CSC 4 patients.The average ages of the patients were (43±5) years.Fundus fluorescein angiography (FFA), indocyanine green angiography(ICGA), optical coherence tomography(OCT) and best corrected visual acuity (BCVA) were examined in all the patients before and after treatment.PDT with the 60%-dose verteporfin (3.6 mg/m 2) was carried out on the CSC eyes.The treated eyes were examined 2 weeks, 1 month and 3 months after PDT.The BCVA, subfoveal choroid thickness, FFA and ICGA findings before and after PDT were compared.The following-up duration was 5 years or more.

ResultsThe BCVA before and 3 months after PDT were 0.5±0.1 and 0.9±0.2, respectively, with a statistically significant difference between them ( t=19.17, P=0.00). The subfoveal choroidal thickness value 3 months after PDT was (326.56±39.47) μm, which was significantly reduced in comparison with (486.24±47.53) μm before PDT ( t=25.17, P=0.00). FFA and ICGA showed that the leakage of fluorescein (hyperfluorescence) was disappeared in all the treated eyes.No systemic or local adverse effects and recurrence were observed during the follow-up period.

ConclusionsOn the basis of the results of this study and available information, 60%-dose verteporfin PDT seems to have a better long-term efficacy and safety than full-dose verteporfin in treating chronic CSC.

Central serous chorioretinopathy/therapy;Photochemotherapy;Verteporfin/dosage;Fundus fluorescein angiography;Indocyanine green;Tomography, optical coherence;Visual acuity
Dong Daoquan, Email: mocdef.3ab61qdgnodrd
Copyright by Chinese Medical Association
No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
引用本文

董道权,董应丽,王志立,等. 60%剂量维替泊芬光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变的远期效果及安全性[J]. 中华实验眼科杂志,2015,33(10)：945-948.

DOI:10.3760/cma.j.issn.2095-0160.2015.10.017

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价

版权归中华医学会所有。

未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。

除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

中心性浆液性脉络膜视网膜病变(central serous chorioretinopathy，CSC)是一种常见的眼底病变，临床上多见于青中年男性，主要表现为中心视野遮挡感，视物发暗、变小或变形，视力下降等 [ 1 ]。近年来随着眼科影像技术的发展，尤其是吲哚青绿血管造影(indocyanine green angiography，ICGA)和OCT的应用，对其临床特点和病理生理机制的认识取得了长足进步。临床上大多数急性CSC病程较短，具有自限性，视力预后良好，但有部分慢性CSC病程迁延，反复发作，引起进行性视力下降，则预后不良。近年来临床研究表明，荧光素眼底血管造影(fundus fluorescein angiography，FFA)联合ICGA与OCT引导的光动力疗法(photodynamic therapy，PDT)是有效的临床治疗措施，但是其远期效果和安全性的临床研究较少。本研究中对PDT治疗的慢性CSC患者随访观察5年以上，以探讨PDT治疗慢性CSC的远期临床效果及安全性。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
Liu DT , Fok AC , Chan W ,et al. Central serous chorioretinopathy[M]// Ryan SJ . Retina. 5th ed. New York：ELSEVIER Saunders, 2012:1291-1304.
返回引文位置Google Scholar
百度学术
万方数据
[2]
Yannuzzi LA , Slakter JS , Gross NE ,et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy：a pilot study[J]．Retina, 2003,23(3):288-298.
返回引文位置Google Scholar
百度学术
万方数据
[3]
王文吉．中心性浆液性脉络膜视网膜病变[J]．中国眼耳鼻喉科杂志， 2014，14(1):2-4.
返回引文位置Google Scholar
百度学术
万方数据
[4]
Yannuzzi LA . Type-A behavior and central serous chorioretinopathy[J]．Retina, 1987,7(2):111-131.
返回引文位置Google Scholar
百度学术
万方数据
[5]
Gallego-Pinazo R , Marsiglia M , Mrejen S ,et al. Outer retinal tubulations in chronic central serous chorioretinopathy[J]．Graefe's Arch Clin Exp Ophthalmol, 2013,251(6):1655-1656. doi： 10.1007/s00417-012-2151-0 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
Barbazetto IA , Cinquini M , Takahashi BS ,et al. Central serous chorioretinopathy and peripheral retinal neovascularization[J]．Retin Cases Brief Rep, 2009,3(2):224-227. doi： 10.1097/ICB.0b013e31816b31e3 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
Chan WM , Liu DT , Chan CK ,et al. Peripheral retinal neovascularization in bullous central serous chorioretinopathy[J]．Eye (Lond), 2004,18(12):1275-1277. doi： 10.1038/sj.eye.6701399 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Gass JD , Little H ．Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy[J]．Ophthalmology, 1995,102(5):737-747.
返回引文位置Google Scholar
百度学术
万方数据
[9]
Akiyama K , Kawamura M , Ogata T ,et al. Retinal vascular loss in idiopathic central serous chorioretinopathy with bullous retinal detachment[J]．Ophthalmology, 1987,94(12):1605-1609.
返回引文位置Google Scholar
百度学术
万方数据
[10]
文峰，吉宇莹．重视中心性浆液性脉络膜视网膜病变的鉴别诊断[J]．中华实验眼科杂志， 2014，32(12):1057-1060. doi： 10.3760/cma.j.issn.2095-0160.2014.12.001 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
张静琳，吴德正，吴斌斌，等．OCT和FFA联合检测对中心性浆液性脉络膜视网膜病变发病机制的研究[J]．中华实验眼科杂志， 2011，29(8):724-727. doi： 10.3760/cma.j.issn.2095-0160.2011.08.013 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
陈有信，张承芬，韩宝玲．中心性浆液性脉络膜视网膜病变靛青绿血管造影[J]．中华眼科杂志， 1997，33(4):255-258.
返回引文位置Google Scholar
百度学术
万方数据
[13]
Valmaggia C , Niederberger H ．Photodynamic therapy in the treatment of chronic central serous chorioretinopathy[J]．Klin Monbl Augenheilkd, 2006,223(5):372-375. doi： 10.1055/s-2006-926567 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
Chan WM , Lam DS , Lai TY ,et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin：a novel treatment at the primary disease level[J]．Br J Ophthalmol, 2003,87(12):1453-1458. doi： 10.1136/bjo.87.12.1453 .
返回引文位置Google Scholar
百度学术
万方数据
[15]
Taban M , Boyer DS , Thomas EL ,et al. Chronic central serous chorioretinopathy：photodynamic therapy[J]．Am J Ophthalmol, 2004,137(6):1073-1080.
返回引文位置Google Scholar
百度学术
万方数据
[16]
Zhao MW , Zhou P , Xiao HX ,et al. Photodynamic therapy for acute central serous chorioretinopathy：the safe effective lowest dose of verteporfin[J]．Renita, 2009,29(8):1155-1161. doi： 10.1097/IAE.0b013e3181a6c028 .
返回引文位置Google Scholar
百度学术
万方数据
[17]
Piccolino FC , de la Longrais RR , Ravera G ,et al. The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy[J]．Am J Ophthalmol, 2005,139(1):87-99.
返回引文位置Google Scholar
百度学术
万方数据
[18]
Nicholson B , Noble J , Forooghian F ,et al. Central serous chorioretinopathy：update on pathophysiology and treatment[J]．Surv Ophthalmol, 2013,58(2):103-126. doi： 10.1016/j.survophthal.2012.07.004 .
返回引文位置Google Scholar
百度学术
万方数据
[19]
Fujita K , Imamura Y , Shinoda K ,et al. Quantification of metamorphopsia in chronic central serous chorioretinopathy after half-dose verteporfin photodynamic therapy[J]．Retina, 2014,34(5):964-970. doi： 10.1097/IAE.0000000000000027 .
返回引文位置Google Scholar
百度学术
万方数据
[20]
Oh BL , Yu HG . Choroidal thickness after full-fluence and half-fluence photodynamic therapy in chronic central serous chorioretinopathy[J]．Retina, 2015,35(8):1555-1560. doi： 10.1097/IAE.0000000000000511 .
返回引文位置Google Scholar
百度学术
万方数据
[21]
Nicoló M , Eandi CM , Alovisi C ,et al. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy[J]．Am J Ophthalmol, 2014,157(5):1033-1037. doi： 10.1016/j.ajo.2014.01.022 .
返回引文位置Google Scholar
百度学术
万方数据
[22]
李略，李东辉，杨治坤，等．中心性浆液性脉络膜视网膜病变眼底血管造影及脉络膜厚度分析[J]．中华眼科杂志， 2012，48(10):878-882. doi： 10.3760/cma.j.issn.0412-4081.2012.10.005 .
返回引文位置Google Scholar
百度学术
万方数据
[23]
Kim YK , Ryoo NK , Woo SJ ,et al. Choroidal thickness changes after photodynamic therapy and recurrence of chronic central serous chorioretinopathy[J]．Am J Ophthalmol, 2015,160(1):72-84. doi： 10.1016/j.ajo.2015.04.011 .
返回引文位置Google Scholar
百度学术
万方数据
[24]
Moon JW , Yu HG , Kim TW ,et al. Prognostic factors related to photodynamic therapy for central serous chorioretinopathy[J]．Graefe's Arch Clin Exp Ophthalmol, 2009,247(10):1315-1323. doi： 10.1007/s00417-009-1104-8 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
董道权，Email： mocdef.3ab61qdgnodrd
B
本研究与文中所涉及的产品和设备制造商及销售公司均无任何利益关系
评论 （0条）
注册
登录
时间排序
暂无评论，发表第一条评论抢沙发
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照

你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持：

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大